D
- Direct-acting antiviral agents (DAAs): DAAs refer to the array of small-molecule compounds that have been designed and are currently being studied to target specific HCV enzymes. Among those furthest along in development include the NS3/4A protease inhibitors and the NS5B polymerase inhibitors.